200 APS patients tracked to uncover Real-World clot recurrence rates
NCT ID NCT07178925
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 200 adults with antiphospholipid syndrome (APS) to see how often blood clots return and how well current treatments work. Researchers will also look at treatment side effects, risk factors, and death rates. No new treatment is being tested; the goal is to gather updated information to improve future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide updated, real-world data on how often blood clots return in APS patients and help guide better treatment decisions.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly improve patient outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME (APS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University hospital of Rouen
RECRUITINGRouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental biologic aims to stop recurrent clots in antiphospholipid syndrome
- New drug trial aims to tame rare clotting disorder
- New drug RAY121 tested for Long-Term control of autoimmune diseases
- New drug targets immune overdrive in six rare diseases
- New cell therapy hopes to tame tough autoimmune diseases
- Experimental cell therapy takes on lupus and other autoimmune diseases